OBJECTIVE: To investigate the influence of oral contraceptives on cytochrome P450 3A4 (P450NF) activity. METHODS: In 23 healthy women, the pharmacokinetics of nifedipine and its main metabolite dehydronifedipine in plasma were assessed after a single oral dose, prior to and after intake of one of two oral contraceptive formulations, one containing 2 mg dienogest and 0.03 mg ethinylestradiol (group A) and the other containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B). RESULTS: While the intake of two oral contraceptives for 21 days did not influence the plasma concentration-time curve of unchanged nifedipine, mean AUC0-23.5 h and the mean Cmax values of dehydronifedipine were significantly lower in both groups tested/(24% in group A and 25% in group B). This observation may indicate a reduced formation rate of metabolites and reflects an inhibition of cytochrome P450 3A4 activity. The activation of the same or other metabolic degradation mechanism(s) could explain this result. CONCLUSION: The investigation presented demonstrates the importance of metabolite measurement when in vivo studies are undertaken to investigate different influences on drug metabolizing ability.
RCT Entities:
OBJECTIVE: To investigate the influence of oral contraceptives on cytochrome P450 3A4 (P450NF) activity. METHODS: In 23 healthy women, the pharmacokinetics of nifedipine and its main metabolite dehydronifedipine in plasma were assessed after a single oral dose, prior to and after intake of one of two oral contraceptive formulations, one containing 2 mg dienogest and 0.03 mg ethinylestradiol (group A) and the other containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol (group B). RESULTS: While the intake of two oral contraceptives for 21 days did not influence the plasma concentration-time curve of unchanged nifedipine, mean AUC0-23.5 h and the mean Cmax values of dehydronifedipine were significantly lower in both groups tested/(24% in group A and 25% in group B). This observation may indicate a reduced formation rate of metabolites and reflects an inhibition of cytochrome P450 3A4 activity. The activation of the same or other metabolic degradation mechanism(s) could explain this result. CONCLUSION: The investigation presented demonstrates the importance of metabolite measurement when in vivo studies are undertaken to investigate different influences on drug metabolizing ability.
Entities:
Keywords:
Biology; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents; Contraceptive Methods--pharmacodynamics; Developed Countries; Europe; Family Planning; Germany; Metabolic Effects--women; Oral Contraceptives, Combined--pharmacodynamics; Oral Contraceptives--pharmacodynamics; Physiology; Research Methodology; Research Report; Western Europe; Women
Authors: Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall Journal: Br J Clin Pharmacol Date: 2002-01 Impact factor: 4.335
Authors: David M Haas; Sara K Quinney; Jayanti M Clay; Jamie L Renbarger; Mary F Hebert; Shannon Clark; Jason G Umans; Steve N Caritis Journal: Am J Perinatol Date: 2012-08-08 Impact factor: 1.862
Authors: Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde Journal: Drug Saf Date: 2016-11 Impact factor: 5.606
Authors: Margit Fröhlich; Jürgen Burhenne; Meret Martin-Facklam; Johanna Weiss; Michael von Wolff; Thomas Strowitzki; Ingeborg Walter-Sack; Walter E Haefeli Journal: Br J Clin Pharmacol Date: 2004-03 Impact factor: 4.335
Authors: Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod Journal: Clin Pharmacokinet Date: 2005 Impact factor: 5.577